New Therapies for Uremic Secondary Hyperparathyroidism

Journal of Renal Nutrition

Volumn 16, Issue 2, 2006, Pages 87-99

  Torres, Pablo Ureña ^a,b   Prié, Dominique ^a   Beck, Laurent ^a   Friedlander, Gérard ^a  

^a Clinique de l'Orangerie Aubervilliers   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; PARATHYROID HORMONE; PARATHYROID HORMONE RECEPTOR 1; PHOSPHATE;

ACIDOSIS; BLOOD; CELL DIVISION; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; HYPOCALCEMIA; IMMUNOLOGY; PARATHYROID GLAND; PARATHYROIDECTOMY; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW; SECONDARY HYPERPARATHYROIDISM; SECRETION; UREMIA; VITAMIN D DEFICIENCY;

ACIDOSIS; ANTIBODIES; CELL DIVISION; HUMANS; HYPERPARATHYROIDISM, SECONDARY; HYPOCALCEMIA; PARATHYROID GLANDS; PARATHYROID HORMONE; PARATHYROIDECTOMY; PHOSPHATES; RECEPTOR, PARATHYROID HORMONE, TYPE 1; UREMIA; VITAMIN D DEFICIENCY;

EID: 33645294113     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2006.01.011     Document Type: Review

References (117)

1. E.W. Young, T. Akiba, J.M. Albert Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS) Am J Kidney Dis 44 2004 34 38
2. E. Slatopolsky, S. Caglar, J.P. Pennell On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog J Clin Invest 50 1971 492 499
3. G.M. London, A.P. Guerin, S.J. Marchais Arterial media calcification in end-stage renal disease Impact on all-cause and cardiovascular mortality Nephrol Dial Transplant 18 2003 1731 1740
4. S.G. Massry, M. Smogorzewski Mechanisms through which parathyroid homone mediates its deleterious effects on organ function in uremia Semin Nephrol 14 1994 219 231
5. S.G. Rostand, T.B. Drueke Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure Kidney Int 56 1999 383 392
6. K. Amann, E. Ritz Cardiac disease in chronic uremia Pathophysiology Adv Ren Replace Ther 4 1997 212 224
7. K. Amann, J. Tornig, C. Flechtenmacher Blood-pressure-independent wall thickening of intramyocardial arterioles in experimental uraemia Evidence for a permissive action of PTH Nephrol Dial Transplant 10 1995 2043 2048
8. M. Kosch, M. Hausberg, K. Vormbrock Impaired flow-mediated vasodilation of the brachial artery in patients with primary hyperparathyroidism improves after parathyroidectomy Cardiovasc Res 47 2000 813 818
9. 4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients J Am Soc Nephrol 12 2001 2131 2138
10. N.K. Foundation K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease Am J Kidney Dis 42 2003 S1 S202
11. E.R. Gagné, P. Ureña, S. Leite-Silva Short and long-term efficacity of total parathyroidectomy with immediate autografting compared with subtotal parathyroidectomy in hemodialysis patients J Am Soc Nephrol 3 1992 1008 1017
12. J. Cunningham, H. Makin How important is vitamin D deficiency in uraemia? Nephrol Dial Transplant 12 1997 16 18
13. J.B. Eastwood, E. Harris, T.C.B. Stamp Vitamin-D deficiency in the osteomalacia of chronic renal failure Lancet 1 1976 1209 1211
14. A. Ghazali, P. Fardellone, A. Pruna Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser's zones independent of calcitriol? Kidney Int 55 1999 2169 2177
15. R.E. LaClair, R.N. Hellman, S.L. Karp Prevalence of calcidiol deficiency in CKD A cross-sectional study across latitudes in the United States Am J Kidney Dis 45 2005 1026 1033
16. A.J. Brown, M. Zhong, J. Finch The role of calcium and 1,25-dihydroxyvitamin D3 in the regulation of vitamin D receptor expression by rat parathyroid glands Endocrinology 136 1995 1419 1425
17. S.R. Patel, H.Q. Ke, C.H. Hsu Regulation of calcitriol receptor and its mRNA in normal and renal failure rats Kidney Int 1994 1994 1020 1027
18. L.A. Stevens, O. Djurdjev, S. Cardew Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality Evidence for the complexity of the association between mineral metabolism and outcomes J Am Soc Nephrol 15 2004 770 779
19. M. Teng, M. Wolf, M.N. Ofsthun Activated injectable vitamin D and hemodialysis survival A historical cohort study J Am Soc Nephrol 16 2005 1115 1125
20. T.B. Drueke Control of secondary hyperparathyroidism by vitamin D derivatives Am J Kidney Dis 37 2001 S58 S61
21. M. Kubrusly, E.R. Gagne, P. Urena Effect of 22-oxa-calcitriol on calcium metabolism in rats with severe secondary hyperparathyroidism Kidney Int 44 1993 551 556
22. J. Silver, R. Kilav, T. Naveh-Many Mechanisms of secondary hyperparathyroidism Am J Physiol Renal Physiol 283 2002 F367 F376
23. A.J. Felsenfeld Considerations for the treatment of secondary hyperparathyroidism in renal failure J Am Soc Nephrol 8 1997 993 1004
24. F. Llach Hyperphosphatemia in end-stage renal disease patients Pathophysiological consequences Kidney Int Suppl 73 1999 S31 S37
25. M. Aparicio, C. Combe, M.H. Lafage In advanced renal failure, dietary phosphorus restriction reverses hyperparathyroidism independent of changes in the levels of calcitriol Nephron 63 1993 122 123
26. G.M. Chertow, K.J. Martin Current and future therapies for the medical management of secondary hyperparathyroidism Sem Dial 11 1998 267 270
27. J.P. vandenBergh, M.A. Gelens, H.A. Klaassen Efficacy and tolerance of three different calcium acetate formulations in hemodialysis patients Neth J Med 55 1999 222 228
28. A.J. Hutchison, B. Maes, J. Vanwalleghem Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia A 6-month, randomized, comparative trial versus calcium carbonate Nephron Clin Pract 100 2005 c8 c19
29. J.R. Litzow, J. Lemann Jr, E.J. Lennon The effect of treatment of acidosis on calcium balance in patients with chronic azotemic renal disease J Clin Invest 46 1967 280 286
30. J. Green, G. Maor Effect of metabolic acidosis on the growth hormone/IGF-I endocrine axis in skeletal growth centers Kidney Int 57 2000 2258 2267
31. E. McSherry, R.C. Morris Attainment and maintenance of normal stature with alkali therapy in infants and children with classic renal tubular acidosis J Clin Invest 61 1978 509 527
32. A. Lefebvre, M.C. deVernejoul, J. Gueris Optimal correction of acidosis changes progression of dialysis osteodystrophy Kidney Int 36 1989 1112 1118
33. D. Sudhaker Rao, Z.H. Han, E.R. Phillips Reduced vitamin D receptor expression in parathyroid adenomas Implications for pathogenesis Clin Endocrinol (Oxf) 53 2000 373 381
34. Y.C. Li, A.E. Pirro, M. Amling Targeted ablation of the vitamin D receptor An animal model of vitamin D-dependent rickets type II with alopecia Proc Natl Acad Sci U S A 94 1997 9831 9835
35. Y.C. Li, M. Amling, A.E. Pirro Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice Endocrinology 139 1998 4391 4396
36. D. Goltzman, D. Miao, D.K. Panda Effects of calcium and of the Vitamin D system on skeletal and calcium homeostasis Lessons from genetic models J Steroid Biochem Mol Biol 89-90 2004 485 489
37. D.K. Panda, S. AI Kawas, M.F. Seldin 25-hydroxyvitamin D 1 alpha-hydroxylase Structure of the mouse gene, chromosomal assignment, and developmental expression J Bone Miner Res 16 2001 46 56
38. J. Gogusev, P. Duchambon, B. Hory Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism Kidney Int 51 1997 328 336
39. A.J. Brown, M. Zhong, J. Finch Rat calcium-sensing receptor is regulated by vitamin D but not by calcium Am J Physiol 270 1996 F454 F460
40. E. Rodica, G. Adler, O. Kifor Calcium-sensing receptor expression and regulation by extracellular calcium in the AtT-20 pituitary cell line Mol Endocrinol 10 1996 555 565
41. N. Yarden, I. Lavelin, O. Genina Expression of calcium-sensing receptor gene by avian parathyroid gland in vivo Relationship to plasma calcium Gen Comp Endocrinol 117 2000 173 181
42. E.M. Brown Physiology and pathophysiology of the extracellular calcium-sensing receptor Am J Med 106 1999 238 253
43. M. Mizobuchi, I. Hatamura, H. Ogata Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency J Am Soc Nephrol 15 2004 2579 2587
44. C. Autry, O. Kifor, E. Brown Ca2+ receptor mRNA and protein increase in the rat parathryoid gland with advancing age J Endocrinol 153 1997 437 444
45. P.K. Nielsen, A.K. Rasmussen, R. Butters Inhibition of PTH secretion by interleukin-1 beta in bovine parathyroid glands in vitro is associated with an up-regulation of the calcium- sensing receptor mRNA Biochem Biophys Res Commun 238 1997 880 885
46. E.M. Brown, M.F. Brennan, S. Hurwitz Dispersed cells prepared from human parathyroid glands Distinct calcium sensitivity of adenomas vs. primary hyperplasia J Clin Endocrinol Metab 46 1978 267 275
47. E.M. Brown, D.G. Gardner, M.F. Brennan Calcium-regulated parathyroid hormone release in primary hyperparathyroidism studies in vitro with dispersed parathyroid cells Am J Med 66 1979 923 931
48. E.M. Brown, E.M. Rown, R.E. Wilson Abnormal regulation of parathyroid hormone release by calcium in secondary hyperparathyroidism due to chronic renal failure J Clin Endocrinol Metab 54 1982 172 179
49. J.F. Habener Responsiveness of neoplastic and hyperplastic parathyroid tissue to calcium in vitro J Clin Invest 62 1978 436
50. F. Caligara, A. Giagrande, P. Allaria The PTH-calcium relationship curve in secondary hyperparathyroidism, an index of sensitivity and suppressibility of parathyroid glands Nephrol Dial Transplant 11 1996 136 141
51. H. Cardinal, J.H. Brossard, L. Roy The set point of parathyroid hormone stimulation by calcium is normal in progressive renal failure J Clin Endocrinol Metab 83 1998 3839 3844
52. P. Messa, C. Vallone, G. Mioni Direct in vivo assessment of parathyroid hormone-calcium relationship curve in renal patients Kidney Int 46 1994 1713 1720
53. M. Pahl, A. Jara, J. Bover The set point of calcium and the reduction of parathyroid hormone in hemodialysis patients Kidney Int 49 1996 226 231
54. J.A. Ramirez, W.G. Goodman, J. Gornbein Direct in vivo comparison of calcium-regulated parathyroid hormone secretion in normal volunteers and patients with secondary hyperparathyroidism J Clin Endocrinol Metab 76 1993 1489 1494
55. J.A. Ramirez, W.G. Goodman, T.R. Belin Calcitriol therapy and calcium-regulated PTH secretion in patients with secondary hyperparathyroidism Am J Physiol 267 1994 E961 E967
56. S. Schindler, M. Mannstadt, P. Urena PTH secretion in patients with chronic renal failure assessed by a modified CiCa clamp method Effects of 1- year calcitriol therapy Clin Nephrol 61 2004 253 260
57. J.A. Delmez, C. Tindira, P. Grooms Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D. A role for increased sensitivity to calcium J Clin Invest 83 1989 1349 1355
58. R. Dunlay, M. Rodriguez, A.J. Felsenfeld Direct inhibitory effect of calcitriol on parathyroid function (sigmoidal curve) in dialysis Kidney Int 36 1989 1093 1098
59. S. Bas, E. Aguilera-Tejero, A. Bas The influence of the progression of secondary hyperparathyroidism on the set point of the parathyroid hormone-calcium curve J Endocrinol 184 2005 241 247
60. M. Rodriguez, F. Caravaca, E. Fernandez Evidence for both abnormal set point of PTH stimulation by calcium and adaptation to serum calcium in hemodialysis patients with hyperparathyroidism J Bone Miner Res 12 1997 347 355
61. E.F. Nemeth, M.E. Steffey, L.G. Hammerland Calcimimetics with potent and selective activity on the parathyroid calcium receptor Proc Natl Acad Sci U S A 95 1998 4040 4045
62. L. Hammerland, J. Garrett, B. Hung Allosteric activation of the Ca2+ receptor in xenopus laevis oocytes by NPS 467 or NPS 568 Mol Pharmacol 53 1998 1083 1088
63. G.A. Block, K.J. Martin, A.L. deFrancisco Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis N, Engl J Med 350 2004 1516 1525
64. J. Coburn, Y. Barri, S. Turner Single doses of the calcimimetic AMG-073 reduce parathyroid hormone levels in a dose dependent manner in hemodialysis patients with secondary hyperparathyroidism J Am Soc Nephrol 11 2000 573A
65. P. Ureña, C. Basile, G. Grateau Short-term effects of parathyroidectomy on plasma biochemistry in chronic uremia A prospective study Kidney Int 36 1989 120 126
66. M. Van Abel, J.G.J. Hoederop, J.P.T.M. Van Leeuwen Down-regulation of Ca2+ transporters in kidney and duodenum by the calcimimetic compound NPS R-467 J Am Soc Nephrol 14 2003 SA-P073 (abstr)
67. T. Drueke, J. Cunningham, W. Goodman Short-term treatment of secondary hyperparathyroidism (SHTP) with the calcimimetic agent AMG 073 J Am Soc Nephrol 12 2001 764A
68. P. Urena, N. Legoupil, M.C. de Vernejoul Sustained control of uraemic secondary hyperparathyroidism (SHPT) after three years of treatment with the calcimimetic Cinacalcet HCL A single centre experience 2003 Poster presented at the 40th ERA-EDTA World Congress of Nephrology, Berlin
69. L.D. Quarles, D.J. Sherrard, S. Adler The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease J Am Soc Nephrol 14 2003 575 583
70. J.S. Lindberg, S.M. Moe, W.G. Goodman The calcimimetic AMG 073 reduces parathyroid hormone and calcium × phosphorus in secondary hyperparathyroidism Kidney Int 63 2003 248 254
71. N. Mittman, F. Finkelstein, B. Culleton Cinacalcet HCL (Sensipar) for the management of secondary hyperparathyroidism in study patients receiving peritoneal dialysis J Am Soc Nephrol 15 2004 280A
72. D.A. Bushinsky Cinacalcet HCL in secondary hyperparathyroidism. Official Evening Symposium of the American Society of Nephrology (ASN) 2004 St. Louis, MO, October 28-November 1
73. S.M. Moe, G.M. Chertow, J.W. Coburn Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCL Kidney Int 67 2005 760 771
74. S.M. Moe, S.M. Sprague, J. Cunningham Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCL Nephrol Dial Transplant 20 2005 2186 2193
75. J. Cunningham, M. Danese, K. Olson Effects of the calcimimetic cinacalcet HCL on cardiovascular disease, fracture and health-related quality of life in secondary hyperparathyroidism Kidney Int 68 2005 1793 1800
76. P. Evenepoel, K. Claes, D. Kuypers Natural history of parathyroid function and calcium metabolism after kidney transplantation A single-centre study Nephrol Dial Transplant 19 2004 1281 1287
77. A.E. Kruse, U. Eisenberger, F.J. Frey The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism Nephrol Dial Transplant 20 2005 1311 1314
78. A.L. Serra, A.A. Schwarz, F.H. Wick Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism Nephrol Dial Transplant 20 2005 1315 1319
79. S.J. Silverberg, H.G. Bone 3rd, T.B. Marriott Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism N Engl J Med 337 1997 1506 1510
80. M.R. Rubin, J. Sliney, S.J. Silverberg Clinical course of 10 patients with inoperable parathyroid carcinoma treated with the calcimimetic cinacalcet HCL J Bone Miner Res 2004 F497 (abstr)
81. O. Kifor, A. McElduff, M.S. Leboff Activating antibodies to the calcium-sensing receptor in two patients with autoimmune hypoparathyroidism J Clin Endocrinol Metab 89 2004 548 556
82. O. Kifor, F. Moore, P. Wang Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism J Clin Endocrinol Metab 81 1996 1598 1606
83. J.C. Pallais, O. Kifor, Y.B. Chen Acquired hypocalciuric hypercalcemia due to autoantibodies against the calcium-sensing receptor N Engl J Med 351 2004 362 369
84. E. Hindie, P. Urena, C. Jeanguillaume Preoperative imaging of parathyroid glands with technetium-99m-labelled sestamibi and iodine-123 subtraction scanning in secondary hyperparathyroidism Lancet 353 1999 2200 2204
85. C. Jeanguillaume, P. Urena, E. Hindie Secondary hyperparathyroidism Detection with I-123-Tc-99m-sestamibi subtraction scintigraphy versus US Radiology 207 1998 207 213
86. Y. Tanaka, H. Seo, Y. Tominaga Factors related to the recurrent hyperfunction of autografts after total parathyroidectomy in patients with severe secondary hyperparathyroidism Surg Today 23 1993 220 227
87. Y. Tominaga, A. Katayama, T. Sato Re-operation is frequently required when parathyroid glands remain after initial parathyroidectomy for advanced secondary hyperparathyroidism in uraemic patients Nephrol Dial Transplant 18 suppl 3 2003 65 70 iii
88. E. Hindie, D. Melliere, C. Jeanguillaume Unilateral surgery for primary hyperparathyroidism on the basis of technetium Tc 99m sestamibi and iodine 123 subtraction scanning Arch Surg 135 2000 1461 1468
89. P. Miccoli Parathyroid surgery We only need a minimal surgical approach J Endocrinol Invest 28 2005 570 573
90. M. Fukagawa, M. Kitaoka, Y. Tominaga Guidelines for percutaneous ethanol injection therapy of the parathyroid glands in chronic dialysis patients Nephrol Dial Transplant 18 suppl 3 2003 31 33 iii
91. K. Shiizaki, I. Hatamura, S. Negi Percutaneous maxacalcitol injection therapy regresses hyperplasia of parathyroid and induces apoptosis in uremia Kidney Int 64 2003 992 1003
92. K. Shiizaki, S. Negi, I. Hatamura Biochemical and cellular effects of direct maxacalcitol injection into parathyroid gland in uremic rats J Am Soc Nephrol 16 2005 97 108
93. K. Shiizaki, S. Negi, M. Mizobuchi Effect of percutaneous calcitriol injection therapy on secondary hyperparathyroidism in uraemic patients Nephrol Dial Transplant 18 suppl 3 2003 42 46 iii
94. M. Cozzolino, Y. Lu, J. Finch p21WAF1 and TGF-alpha mediate parathyroid growth arrest by vitamin D and high calcium Kidney Int 60 2001 2109 2117
95. M. Cozzolino, Y. Lu, T. Sato A critical role for enhanced-TGF α and EGFR expression in the initiation of parathyroid hyperplasia in experimental kidney disease Am J Physiol Renal Physiol 289 2005 F1096 F1102
96. S. Izuta, M. Saneyoshi, T. Sakurai The 5′-triphosphates of 3′-azido-3′-deoxythymidine and 2′, 3′-dideoxynucleosides inhibit DNA polymerase gamma by different mechanisms Biochem Biophys Res Commun 179 1991 776 783
97. A. Falchetti, A. Franchi, C. Bordi Azidothymidine induces apoptosis and inhibits cell growth and telomerase activity of human parathyroid cancer cells in culture J Bone Miner Res 20 2005 410 418
98. O. Bell, E. Gaberman, R. Kilav The protein phosphatase calcineurin determines basal parathyroid hormone gene expression Mol Endocrinol 19 2005 516 526
99. P. D'Amour, J.H. Brossard, L. Rousseau Structure of non-(1-84) PTH fragments secreted by parathyroid glands in primary and secondary hyperparathyroidism Kidney Int 68 2005 998 1007
100. P. Divieti, A.I. Geller, G. Suliman Receptors specific for the carboxyl-terminal region of parathyroid hormone on bone-derived cells Determinants of ligand binding and bioactivity Endocrinology 146 2005 1863 1870
101. P. Divieti, M.R. John, H. Juppner Human PTH-(7-84) inhibits bone resorption in vitro via actions independent of the type 1 PTH/PTHrP receptor Endocrinology 143 2002 171 176
102. T.M. Murray, L.G. Rao, P. Divieti Parathyroid hormone secretion and action Evidence for discrete receptors for the carboxyl-terminal region and related biological actions of carboxyl-terminal ligands Endocr Rev 26 2005 78 113
103. E. Slatopolsky, J. Finch, P. Clay A novel mechanism for skeletal resistance in uremia Kidney Int 58 2000 753 761
104. T. Kihara, H. Ichikawa, H. Morimoto Intravenous vitamin D therapy reduces PTH-(1-84)/large C fragments ratio in chronic hemodialysis patients Nephron Clin Pract 98 2004 c93 c100
105. A.S. Pollock, D.M. Shoback, R.H. Arends Treatment of severe hyperparathyroidism secondary to parathyroid cancer with ABX10241, a fully human monoclonal antibody directed against parathyroid hormone J Am Soc Nephrol 15 2004 279A
106. M. Sahni, H.L. Guenther, H. Fleisch Bisphosphonates act on bone resorption through the mediation of osteoblasts J Clin Invest 91 1993 2004 2011
107. A.M. Inzerillo, M. Zaidi, C.L. Huang Calcitonin The other thyroid hormone Thyroid 12 2002 791 798
108. J.W. Coburn, A.S. Brickman, S.G. Massry Medical treatment in primary and secondary hyperparathyroidism Semin Drug Treat 2 1972 117 135
109. M. Ishida, M. Yamada [Calcitonin for therapy of renal osteodystrophy due to long- term hemodialysis in patients with chronic kidney failure] Nippon Rinsho 49 suppl 1991 725 731
110. J. Matuszkiewicz-Rowinska, S. Niemczyk, J. Przedlacki [Effect of salmon calcitonin on bone mineral density and calcium- phosphate metabolism in chronic hemodialysis patients with secondary hyperparathyroidism] Pol Arch Med Wewn 112 2004 797 803
111. J. Matuszkiewicz-Rowinska, S. Niemczyk, J. Puka [Combined therapy with calcitonin and high doses of active vitamin D3 metabolites in uremic hyperparathyroidism] Pol Arch Med Wewn 96 1996 23 31
112. W.S. Simonet, D.L. Lacey, C.R. Dunstan Osteoprotegerin A novel secreted protein involved in the regulation of bone density Cell 89 1997 309 319
113. I. Avbersek-Luznik, I. Malesic, I. Rus Increased levels of osteoprotegerin in hemodialysis patients Clin Chem Lab Med 40 2002 1019 1023
114. J.J. Kazama Osteoprotegerin and bone mineral metabolism in renal failure Curr Opin Nephrol Hypertens 13 2004 411 415
115. K. Nitta, T. Akiba, K. Uchida The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis Am J Kidney Dis 42 2003 303 309
116. T. Cundy, J. Davidson, M.D. Rutland Recombinant osteoprotegerin for juvenil Paget's disease N Engl J Med 353 2005 918 923
117. T.B. Usdin, C. Gruber, T.I. Bonner Identification and functional expression of a receptor selectively recognizing parathyroid hormone, the PTH2 receptor J Biol Chem 270 1995 15455 15458